title: Cetuximab in the management of colorectal cancer.
abstract: Cetuximab, a chimeric IgG1 monoclonal antibody that targets the ligand-binding domain of the epidermal growth factor receptor (EGFR), is active in metastatic colorectal cancer (mCRC). As an IgG1 antibody, cetuximab may exert its antitumor efficacy through both EGFR antagonism and antibody-dependent cell-mediated cytotoxicity. Clinical trials established the role of cetuximab, particularly with irinotecan, in irinotecan-refractory/heavily pretreated patients. More recent studies show promising activity in second-line treatment after oxaliplatin-based therapy failure, and with first-line chemotherapy, where increased response rates seen with adding cetuximab to first-line therapy for mCRC may increase chances for curative surgery in a population for whom the therapy goal would otherwise be palliative. Cetuximab is generally well tolerated; common toxicities are acne-form rash and hypomagnesemia. Rash intensity is associated with clinical efficacy, and in the future, may be used as a marker for optimal drug exposure. Cetuximab activity in mCRC is not correlated with EGFR expression, and consequently other markers will be needed to identify the most likely responders. Cetuximab has clinically emerged as a core agent, along with 5-fluorouracil, irinotecan, oxaliplatin, and bevacizumab, for overall mCRC management to optimize survival. Ongoing studies are exploring best combinations of cetuximab with these other agents to maximize patient outcome.
authors.affiliation: Division of Medical Oncology, University of Southern California/ Norris, Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA, USA.
authors.forename: Heinz-Josef
authors.initials: HJ
authors.lastname: Lenz
references.citation: J Clin Oncol. 2000 Aug;18(16):2938-47
references.pmid: 10944126
references.citation: Eur J Cancer. 2001 Sep;37 Suppl 4:S9-15
references.pmid: 11597399
references.citation: Lancet. 1998 Oct 31;352(9138):1413-8
references.pmid: 9807987
references.citation: J Am Acad Dermatol. 2007 Feb;56(2):317-26
references.pmid: 17141360
references.citation: Ann Oncol. 2008 Jun;19(6):1141-5
references.pmid: 18281264
references.citation: Tissue Antigens. 2003 Mar;61(3):189-202
references.pmid: 12694568
references.citation: Oncology. 2002;63(1):92-8
references.pmid: 12187077
references.citation: N Engl J Med. 2004 Jul 22;351(4):337-45
references.pmid: 15269313
references.citation: J Clin Oncol. 2006 Jul 20;24(21):3354-60
references.pmid: 16849749
references.citation: Ann Pharmacother. 1994 Feb;28(2):220-6
references.pmid: 8173141
references.citation: J Clin Oncol. 2007 Aug 20;25(24):3712-8
references.pmid: 17704420
references.citation: Cancer Res. 1999 Apr 15;59(8):1935-40
references.pmid: 10213503
references.citation: Clin Colorectal Cancer. 2006 Jul;6(2):152-6
references.pmid: 16945172
references.citation: Int J Cancer. 2007 Feb 15;120(4):781-7
references.pmid: 17096332
references.citation: Ann Oncol. 2007 Feb;18(2):305-10
references.pmid: 17079693
references.citation: Lancet. 2000 Mar 25;355(9209):1041-7
references.pmid: 10744089
references.citation: N Engl J Med. 2004 Jun 3;350(23):2335-42
references.pmid: 15175435
references.citation: J Clin Oncol. 2004 Apr 1;22(7):1209-14
references.pmid: 15051767
references.citation: J Clin Oncol. 2007 Apr 20;25(12):1539-44
references.pmid: 17442997
references.citation: J Clin Oncol. 2004 Apr 1;22(7):1201-8
references.pmid: 14993230
references.citation: Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1384-90
references.pmid: 16979839
references.citation: Clin Cancer Res. 2002 May;8(5):994-1003
references.pmid: 12006511
references.citation: Ann Oncol. 2005 Jan;16(1):102-8
references.pmid: 15598946
references.citation: J Clin Oncol. 2003 Nov 1;21(21):3940-7
references.pmid: 12975461
references.citation: Ann Oncol. 2006 Mar;17(3):450-6
references.pmid: 16303861
references.citation: Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
references.pmid: 11252954
references.citation: J Clin Oncol. 2005 Dec 20;23(36):9441-2
references.pmid: 16361649
references.citation: Cancer. 2000 Jul 1;89(1):74-82
references.pmid: 10897003
references.citation: J Clin Oncol. 2004 Jan 15;22(2):229-37
references.pmid: 14657227
references.citation: Clin Cancer Res. 2007 Mar 1;13(5):1552-61
references.pmid: 17332301
references.citation: Drugs Today (Barc). 2005 Feb;41(2):107-27
references.pmid: 15821783
references.citation: Ann Oncol. 2007 Apr;18(4):738-44
references.pmid: 17208931
references.citation: Blood. 2004 Nov 1;104(9):2635-42
references.pmid: 15226177
references.citation: Cancer Res. 2006 Apr 15;66(8):3992-5
references.pmid: 16618717
references.citation: Lancet. 1998 Oct 31;352(9138):1407-12
references.pmid: 9807986
references.citation: J Clin Oncol. 2007 Oct 10;25(29):4557-61
references.pmid: 17876013
references.citation: Panminerva Med. 2001 Sep;43(3):177-209
references.pmid: 11579331
references.citation: J Clin Oncol. 2006 Oct 20;24(30):4914-21
references.pmid: 17050875
references.citation: Expert Opin Biol Ther. 2006 Nov;6(11):1229-35
references.pmid: 17049019
references.citation: J Clin Oncol. 2005 May 20;23(15):3536-44
references.pmid: 15908664
references.citation: J Clin Oncol. 2007 Aug 1;25(22):3230-7
references.pmid: 17664471
references.citation: Br J Cancer. 2007 Apr 23;96(8):1166-9
references.pmid: 17375050
references.citation: J Clin Oncol. 2005 Aug 1;23(22):5235-46
references.pmid: 16051966
references.citation: Clin Colorectal Cancer. 2005 Apr;5 Suppl 1:S19-27
references.pmid: 15871762
references.citation: J Biol Chem. 2005 Sep 2;280(35):31182-9
references.pmid: 16000298
references.citation: Clin Cancer Res. 1999 Apr;5(4):909-16
references.pmid: 10213228
references.citation: N Engl J Med. 2000 Sep 28;343(13):905-14
references.pmid: 11006366
references.citation: J Clin Oncol. 2008 Nov 20;26(33):5326-34
references.pmid: 18854571
references.citation: Cancer Metastasis Rev. 2005 Dec;24(4):487-99
references.pmid: 16408158
references.citation: J Clin Oncol. 2005 Mar 20;23(9):1803-10
references.pmid: 15677699
references.citation: J Natl Cancer Inst. 2005 Aug 17;97(16):1221-4
references.pmid: 16106027
references.citation: Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):5-13
references.pmid: 16736978
references.citation: Int J Biochem Cell Biol. 1999 Jun;31(6):637-43
references.pmid: 10404636
references.citation: J Natl Compr Canc Netw. 2003 Jan;1(1):40-53
references.pmid: 19764149
references.citation: N Engl J Med. 2006 Feb 9;354(6):567-78
references.pmid: 16467544